Clinical trial
Phase 1/2 Evaluating the Addition of Venetoclax to Standard 3+7 and Midostaurin Induction Treatment in Patients With FLT3-mutated Acute Myeloid Leukemia Eligible to Intensive Chemotherapy - MIDOVEN
NCT07726576 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1/2 Evaluating the Addition of Venetoclax to Standard 3+7 and Midostaurin Induction Treatment in Patients With FLT3-mutated Acute Myeloid Leukemia Eligible to Intensive Chemotherapy - MIDOVEN
- Lead sponsor
- University Hospital, Bordeaux
- Phase
- Phase 1/2
- Overall status
- Not yet recruiting
- Start date
- September 30, 2026
- Completion date
- December 31, 2031
- Enrollment
- 41 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.